Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A amyloid pathway
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
It is now 100 years since the nosological definition of Alzheimer's disease emerged. In the first 80 years, very little progress was made in understanding the mechanisms that caused the brain to degenerate in a remarkably specific fashion (amyloid accumulation with neurofibrillary changes). Over the past 20 years, there has been an explosion of knowledge which continues today at an exponential rate. The molecular pathways underlying the synaptic dysfunction in Alzheimer's disease have delivered many validated therapeutic and diagnostic targets. A variety of therapeutic strategies aimed at disease modification are now in clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 4×
“After the initial sequencing of the N-terminus of Ab derived from cerebral leptomeninges (Glenner and Wong, 1984a, b), we were able to correct and extend the sequence of plaque-derived amyloid, and determine the likely C-terminus (Masters et al., 1985a,b; Kang et al., 1987).”
InfluentialSelf-citationAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 7×
“…between the environment and the risk for Alzheimer’s disease have attracted many A4 soluble dimers (A8), tetramers (A16), etc., forming oligomers (Masters et al., 1985a) Amorphous aggregates (Davies et al., 1988; Huang et al., 2000) Ab-derived diffusible ligands (ADDLs) (Lambert et al., 1998)…”
BackgroundInfluentialSelf-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“…are causally linked to early onset familial Alzheimer’s disease (Levy et al., 1990; van Broeckhoven et al., 1990; Chartier- Harlin et al., 1991; Sherrington et al., 1995); second, gen- etically engineered mice with these mutations (Quon et al., Downloaded from…”
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“…etc., forming oligomers (Masters et al., 1985a) Amorphous aggregates (Davies et al., 1988; Huang et al., 2000) Ab-derived diffusible ligands (ADDLs) (Lambert et al., 1998) b-Balls (Laurents et al., 2005) b-Amy balls (Westlind-Danielsson et al., 2001) Globular Ab oligomer (Barghorn et al., 2005)…”
BackgroundAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“…mice with these mutations (Quon et al., Downloaded from https://academic.oup.com/brain/article-abstract/129/11/2823/291469 by guest on 29 July 2018 1991; Games et al., 1995) recapitulate the human disease in that plaques, perivascular amyloid, neurofibrillary changes and behavioural impairments…”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“…reporting efficacy of compounds derived from plants [ferulic acid (Sultana et al., 2005), green tea extracts (Rezai-Zadeh et al., 2005), curcumin (Yang et al., 2005) and resveratol (Marambaud et al., 2005)], and other natural products [docosahexaenoic acid (Lim et al., 2005), vitamin E…”
BackgroundTau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 2×
“…the endocytosis of the NMDA receptor [mediated in part through a-7 nicotinic receptor, protein phosphatase PP2B and tyrosine phosphatase STEP (Snyder et al., 2005)], the findings that memantine has beneficial behavioural effects in both Ab toxicity models (Yamada et al., 2005) and (i)…”
Background
Cited by
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Self-citationAdlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Self-citationTLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A. J., Penke, B., Rübe, C. E., Walter, J., Heneka, M. T., Hartmann, T., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101121 · Cited by 439
El-Sappagh, S., Alonso, J. M., Islam, S. M. R., Sultan, A. M., & Kwak, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82098-3 · Cited by 363
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
Duce, J. A., & Bush, A. I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.003 · Cited by 283
Rowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 261
Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease
Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L., & Rao, K. S. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200185 · Cited by 177
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
“Consequently, these observations support the concept that bamyloid fuels tauopathy in sAD (Masters and Beyreuther, 2006; Delacourte, 2006).”
BackgroundHigher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia
Zambón, D., Quintana, M., Mata, P., Alonso, R., Benavent, J., Cruz-Sánchez, F., Gich, J., Pocoví, M., Civeira, F., Capurro, S., et al. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.08.015 · Cited by 125
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Self-citationBelinson, H., Lev, D., Masliah, E., & Michaelson, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5633-07.2008 · Cited by 101
Clerx, L., van Rossum, I. A., Burns, L., Knol, D. L., Scheltens, P., Verhey, F., Aalten, P., Lapuerta, P., van de Pol, L., van Schijndel, R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.002 · Cited by 98
“detection of AD might prevent irreversible damage by enabling preventative treatment (Masters and Beyreuther, 2006; Vellas et al., 2007).”
Ma, C., Wang, J., Zhang, J., Chen, K., Li, X., Shu, N., Chen, Y., Liu, Z., & Zhang, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0224-5 · Cited by 21
Metadata
- Authors
- Masters, C. L., & Beyreuther, K.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 2823-2839
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2169966070
- Cited by
- 141
- References
- 43
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.